Join our team! Oncology Physician Job Openings | CTCA
Registration is now open! Advances and Innovations in Interventional Gastroenterology and Gastrointestinal Cancer Care CME Program
Leukemia Awareness Month: Biomarker Testing Proves Vital at Every Stage of AML Care
September 12th 2023For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia.
Read More
Sarcoma Awareness Month: Impact of Molecular Testing and Individualized Treatments
July 19th 2023For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.
Read More
Cancer Immunotherapy Month: Mismatch Repair Deficiency Shapes Tumor-Agnostic Use of Immunotherapy
June 28th 2023The pan-tumor indication for immunotherapy in patients with mismatch repair deficient/microsatellite instability-high cancers has offered new treatment options and emphasized the importance of biomarker testing.
Read More
Behind the FDA Approval: Subcutaneous Epcoritamab for R/R DLBCL
May 19th 2023In an interview with Targeted Oncology, Tycel Phillips, MD, discussed what led to the FDA approval of subcutaneous epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma and how it adds to the current treatment landscape.
Read More
World Ovarian Cancer Day: Biomarkers Shape Treatment Decisions for Ovarian Cancer
May 8th 2023In an interview with Targeted Oncology for World Ovarian Cancer Day, Natalie Godbee, DO, discussed the current state of treatment for advanced ovarian cancer and how oncologists can get the best outcomes for their patients.
Read More
The Impact of Advancements on the Current and Future Multiple Myeloma Landscape
January 4th 2023In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, discussed the impact of new advancements in the treatment of multiple myeloma, like the use of BiTE cells, on the current and future landscape for this patient population.
Read More